BCG vaccine greater benefit the earlier it is used. BCG vaccine is in the early stages of being studied in type I diabetes. BCG vaccine Bacillus Calmette–Guérin (BCG) vaccine is a vaccine primarily used against tuberculosis (TB). In countries where tuberculosis or leprosy is common, one dose is recommended in healthy babies as close to the time of birth as possible. In areas where tuberculosis is not common, only children at high risk are typically immunized, while suspected cases of tuberculosis are individually tested for and treated. Adults who do not have tuberculosis and have not been previously immunized but are frequently
BCG disease outbreak in Finland in the 2000s In practice, however, almost everything that's connected to vaccines is done with the National Public Health Institute. NPHI also does significant research funded by outside sources - ca. 40% of funding is outside, and the policy is to get as much outside funding as possible. Among the biggest funders has been the vaccine giant GlaxoSmithKline between 2003 and 2005. In the 1970s, there was a similar outbreak of BCG osteitis osteomyelitis in some Nordic countries, Sweden and Finland, when a Swedish-Danish BCG vaccine strain was used. To resolve the issue, Sweden discontinued mass BCG vaccinations to newborns, and Finland switched